CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Novt LLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Novt LLC
61 E Main St Ste B
Phone: (302) 658-7581p:302 658-7581 LOS GATOS, CA  95030-6947  United States Fax: (302) 655-5049f:302 655-5049

This company ceased filing statements with the SEC on 8/11/2006.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
NOVT Llc, formerly NOVT Corporation, is a medical device company that is engaged in developing therapeutic solutions for the prevention and treatment of vascular disease. It developed the Beta-Cath System, a hand-held device to deliver beta, a low penetration radiation, to the site of a treated blockage in a coronary artery to inhibit restenosis. Restenosis, the renarrowing of a previously treated artery, is the major limitation of percutaneous transluminal coronary angioplasty (PTCA), a procedure used by interventional cardiologists to open blocked coronary arteries. Coronary stents, metal tubes or coils permanently deployed at a blockage in a coronary artery, were developed to reduce the incidence of restenosis; however, restenosis still occurs in some of the patients who receive bare metal stents. On March 9, 2006, NOVT completed the sale of its vascular brachytherapy (VBT) business to Best Vascular, Inc.
(Source: PRESS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201112/31/2008YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board John J.Quicke 67 4/1/2006 4/1/2006
Chief Financial Officer, Vice President-Finance, Controller Subhash C.Sarda 61 12/17/2004 11/1/2002
Secretary, Director Jack L.Howard 55 4/1/2006 4/1/2006
Director LeonardToboroff 84 4/1/2006 4/1/2006
Director William E.Whitmer 77 10/1/1992 10/1/1992

Business Names
Business Name
Novoste BV
Novoste Corp.
Novoste Corporation
5 additional Business Names available in full report.

General Information
Stock Exchange: OTC
Federal Tax Id: 592787476
Fax Number: (302) 655-5049
Email Address: cjohnson@novoste.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023